Clinical Trial Update: Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus for renal efficacy and safety in autosomal dominant polycystic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Polycystic Kidney | Phase 2 | Status: COMPLETED